JP2016516985A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016516985A5 JP2016516985A5 JP2015562256A JP2015562256A JP2016516985A5 JP 2016516985 A5 JP2016516985 A5 JP 2016516985A5 JP 2015562256 A JP2015562256 A JP 2015562256A JP 2015562256 A JP2015562256 A JP 2015562256A JP 2016516985 A5 JP2016516985 A5 JP 2016516985A5
- Authority
- JP
- Japan
- Prior art keywords
- abnormalities
- pharmaceutical composition
- stem cells
- human subject
- mesenchymal stem
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13382091.0 | 2013-03-15 | ||
| EP13382091 | 2013-03-15 | ||
| PCT/EP2014/055282 WO2014140362A2 (en) | 2013-03-15 | 2014-03-17 | Lymphocyte biomarkers for determining the clinical response to cell therapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019140842A Division JP6883070B2 (ja) | 2013-03-15 | 2019-07-31 | 細胞治療に対する臨床反応を決定するためのリンパ球バイオマーカー |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016516985A JP2016516985A (ja) | 2016-06-09 |
| JP2016516985A5 true JP2016516985A5 (enExample) | 2017-04-27 |
| JP6567430B2 JP6567430B2 (ja) | 2019-08-28 |
Family
ID=48044710
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015562256A Active JP6567430B2 (ja) | 2013-03-15 | 2014-03-17 | 細胞治療に対する臨床反応を決定するためのリンパ球バイオマーカー |
| JP2019140842A Expired - Fee Related JP6883070B2 (ja) | 2013-03-15 | 2019-07-31 | 細胞治療に対する臨床反応を決定するためのリンパ球バイオマーカー |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019140842A Expired - Fee Related JP6883070B2 (ja) | 2013-03-15 | 2019-07-31 | 細胞治療に対する臨床反応を決定するためのリンパ球バイオマーカー |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US10660920B2 (enExample) |
| EP (2) | EP3581932A1 (enExample) |
| JP (2) | JP6567430B2 (enExample) |
| AU (2) | AU2014230014B2 (enExample) |
| CA (2) | CA2906299C (enExample) |
| DK (1) | DK2972368T3 (enExample) |
| ES (1) | ES2748825T3 (enExample) |
| HU (1) | HUE046531T2 (enExample) |
| IL (1) | IL241586B (enExample) |
| PL (1) | PL2972368T3 (enExample) |
| PT (1) | PT2972368T (enExample) |
| SG (1) | SG11201507521UA (enExample) |
| WO (1) | WO2014140362A2 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060045872A1 (en) | 2004-08-25 | 2006-03-02 | Universidad Autonoma De Madrid Ciudad Universitaria de Cantoblanco | Use of adipose tissue-derived stromal stem cells in treating fistula |
| CA2623353C (en) | 2005-09-23 | 2017-02-21 | Cellerix, S.L. | Cell populations having immunoregulatory activity, method for isolation and uses |
| EP3581932A1 (en) | 2013-03-15 | 2019-12-18 | TiGenix, S.A.U. | Lymphocyte biomarkers for determining the clinical response to cell therapy |
| JP6811724B2 (ja) * | 2015-04-24 | 2021-01-13 | ティジェニクス エス．エー．ユー． | 細胞療法に対する臨床応答を決定するためのバイオマーカー |
| GB201604304D0 (en) * | 2016-03-14 | 2016-04-27 | Tigenix S A U | Adipose tissue-derived stromal stem cells for use in treating refractory complex perianal fistulas in crohn's disease |
| JP7276664B2 (ja) * | 2016-11-11 | 2023-05-18 | ロングエバーオン インコーポレイテッド | 細胞性及び体液性免疫を達成するためのヒト間葉系幹細胞を使用する方法 |
| US20220202868A1 (en) * | 2019-02-27 | 2022-06-30 | Tigenix S.A.U. | Improved stem cell populations for allogeneic therapy |
| WO2021207192A1 (en) * | 2020-04-08 | 2021-10-14 | Figene, Llc | Methods and compositions for allergy and asthma treatment using fibroblasts |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE451113T1 (de) * | 1999-10-20 | 2009-12-15 | Chugai Pharmaceutical Co Ltd | Verwendung von g-csf zur hemmung der gvhd |
| EP2298863B1 (en) * | 2004-03-22 | 2015-07-22 | Mesoblast International Sàrl | Mesenchymal stem cells and uses therefor |
| US20080171047A1 (en) * | 2005-04-22 | 2008-07-17 | Gregg Allen Hadley | Methods of Treating Graft Versus Host Disease |
| CN106692193B (zh) * | 2011-04-06 | 2021-01-05 | 桑比欧公司 | 用于调节外周免疫功能的方法和组合物 |
| EP3581932A1 (en) | 2013-03-15 | 2019-12-18 | TiGenix, S.A.U. | Lymphocyte biomarkers for determining the clinical response to cell therapy |
-
2014
- 2014-03-17 EP EP19187915.4A patent/EP3581932A1/en not_active Withdrawn
- 2014-03-17 HU HUE14712628A patent/HUE046531T2/hu unknown
- 2014-03-17 CA CA2906299A patent/CA2906299C/en active Active
- 2014-03-17 AU AU2014230014A patent/AU2014230014B2/en active Active
- 2014-03-17 EP EP14712628.8A patent/EP2972368B1/en active Active
- 2014-03-17 SG SG11201507521UA patent/SG11201507521UA/en unknown
- 2014-03-17 WO PCT/EP2014/055282 patent/WO2014140362A2/en not_active Ceased
- 2014-03-17 DK DK14712628.8T patent/DK2972368T3/da active
- 2014-03-17 PL PL14712628T patent/PL2972368T3/pl unknown
- 2014-03-17 ES ES14712628T patent/ES2748825T3/es active Active
- 2014-03-17 PT PT147126288T patent/PT2972368T/pt unknown
- 2014-03-17 US US14/776,233 patent/US10660920B2/en active Active
- 2014-03-17 JP JP2015562256A patent/JP6567430B2/ja active Active
- 2014-03-17 CA CA3188652A patent/CA3188652A1/en active Pending
-
2015
- 2015-09-16 IL IL241586A patent/IL241586B/en active IP Right Grant
-
2019
- 2019-07-31 JP JP2019140842A patent/JP6883070B2/ja not_active Expired - Fee Related
-
2020
- 2020-02-05 AU AU2020200807A patent/AU2020200807B2/en active Active
- 2020-04-21 US US16/854,294 patent/US11478511B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015131795A5 (enExample) | ||
| GB2569921A (en) | Bisymmetric comparison of sub-epidermal moisture values | |
| WO2019006005A3 (en) | METHODS AND COMPOSITIONS FOR THE TREATMENT OF MELANOMA | |
| Niknejad et al. | Anticancer effects of human amniotic membrane and its epithelial cells | |
| EA201691516A1 (ru) | Дигидропирролопиридиновые ингибиторы ror-гамма | |
| JP2016500698A5 (enExample) | ||
| WO2017062456A3 (en) | Biomarkers related to interleukin-33 (il-33)-mediated diseases and uses thereof | |
| IN2015DN00376A (enExample) | ||
| EP4353319A3 (en) | Methods of adoptive cell therapy | |
| WO2015148389A3 (en) | Diagnosis of multiple sclerosis in human and animal subjects | |
| EA201790563A1 (ru) | Применение реслизумаба для лечения эозинофильной астмы со степенью тяжести от умеренной до тяжелой | |
| EP4252742A3 (en) | Fluticasone furoate in the treatment of copd | |
| BR112017001971A2 (pt) | ?métodos e composições para diagnosticar e tratar distúrbios inflamatórios intestinais? | |
| JP2012518646A5 (enExample) | ||
| MX2017014857A (es) | Metodos para diagnosticar y evaluar tratamiento para sindrome de cushing. | |
| WO2015120436A3 (en) | Stat3 phosphorylation during graft-versus-host disease | |
| EP4356967A3 (en) | Compounds for use as imaging agents | |
| ME03295B (me) | Inhibitor transfer proteina holesteril estra (cetp) i farmaceutske kompozicije koje sadrže pomenuti inhibitor za upotrebu u tretmanu ili prevenciji kardiovaskularnih bolesтi | |
| WO2016081733A3 (en) | Compositions and methods for modulating at2r activity | |
| BR112012030051A2 (pt) | índice de saúde oral | |
| WO2019055776A3 (en) | Compositions and methods for treatment of diseases involving cxcl1 function | |
| Chastek et al. | C31 CLINICAL ASTHMA I: The Few Who Use The Most: Costs Of Severe And Persistent Asthma In A Us Managed Care Plan | |
| EP4328245A3 (en) | Antibodies for use in treating conditions related to specific pcsk9 variants in specific patients populations | |
| Yanishen et al. | Dentures quality at the stages of its clinical durability | |
| Yelnikova | Problems and perspectives of physical rehabilitation of men with metabolic syndrome at the second period of of mature age |